Structure Therapeutics Inc. 2025-2026 Proxy Voting Records

Description as filed by funds: Election of the nominees for Class III director named below to hold office until the 2029 annual general meeting of shareholders and their successors are duly elected and qualified, or until their earlier death, resignation or removal: Daniel G. Welch

Structure Therapeutics Inc.’s own tally for this item (“Elect Director: Daniel G. Welch”): 161,336,058 for, 3,429,342 against, per its Form 8-K filed June 18, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 55 asset managers below reported 19,574,137 for, 576,006 against, 10,973 abstained.

Showing the 25 largest of 55 asset managers. See all 55 in the interactive database.

Description as filed by funds: Election of the nominees for Class III director named below to hold office until the 2029 annual general meeting of shareholders and their successors are duly elected and qualified, or until their earlier death, resignation or removal: Raymond Stevens, Ph.D.

Structure Therapeutics Inc.’s own tally for this item (“Elect Director: Raymond Stevens, Ph.D.”): 164,373,741 for, 400,929 against, per its Form 8-K filed June 18, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.7% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 55 asset managers below reported 20,150,143 for, 10,973 abstained.

Showing the 25 largest of 55 asset managers. See all 55 in the interactive database.

Description as filed by funds: Election of the nominees for Class III director named below to hold office until the 2029 annual general meeting of shareholders and their successors are duly elected and qualified, or until their earlier death, resignation or removal: Ted W. Love, M.D.

Structure Therapeutics Inc.’s own tally for this item (“Elect Director: Ted W. Love, M.D.”): 164,241,780 for, 533,358 against, per its Form 8-K filed June 18, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.6% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 55 asset managers below reported 20,150,143 for, 10,973 abstained.

Showing the 25 largest of 55 asset managers. See all 55 in the interactive database.

Description as filed by funds: TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS, AS DISCLOSED IN THE PROXY STATEMENT.

Structure Therapeutics Inc.’s own tally for this item (“Proposal 3: Advisory vote on the compensation of the Company's named executive officers On an advisory basis, the shareholders approved the compensation of the Company's named executive officers, as disclosed in the Comp”): 158,547,441 for, 6,187,647 against — passed, per its Form 8-K filed June 18, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 3: Advisory vote on the compensation of the Company's named executive officers On an advisory basis, the shareholders approved the compensation of the Company's named executive officers, as disclosed in the Company's proxy statement for the Annual General Meeting.”
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 55 managers: 18,690,732 for, 1,459,411 against, 10,973 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 168 managers: 53,497,469 for, 1,717,681 against, 196 not voted. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: To ratify the appointment by the Audit Committee of the Board of Directors of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.

Structure Therapeutics Inc.’s own tally for this item (“2. Ratification of Appointment of Independent Registered Public Accounting Firm”): 164,767,215 for, 20,784 against — passed, per its Form 8-K filed June 18, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 2: Ratification of Appointment of Independent Registered Public Accounting Firm The Company's shareholders ratified the appointment by the Audit Committee of the Company's Board of Directors of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal …”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 55 asset managers below reported 20,150,143 for, 10,973 abstained.

Showing the 25 largest of 55 asset managers. See all 55 in the interactive database.